"Influence of Preoperative Immunomodulation by Oral Impact® on Postoperative Complications Following Cystectomies and Nephrectomies (IMPACTURO)
Primary Purpose
Urological Manifestations
Status
Not yet recruiting
Phase
Phase 3
Locations
Study Type
Interventional
Intervention
ORAL IMPACT treatment
control
Sponsored by
About this trial
This is an interventional treatment trial for Urological Manifestations focused on measuring cystectomy,, nephrectomy,, laparotomies, reduction of postoperative complications
Eligibility Criteria
Inclusion Criteria:
- 18 years of age and older
- Scheduled major urological surgery: scheduled: cystectomy, nephrectomy, other laparotomies.
- Having expressed their free and informed consent.
- Affiliated to a social security scheme
Exclusion Criteria:
Immune deficiency.
- HIV infection.
- Curative surgery for chronic urinary tract infection.
- Urgent surgery.
- Inability to take oral impact 7 days before surgery.
- Unstable psychiatric state.
- Infection with COVID 19 during postoperative stay.
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Other
Arm Label
ORAL impact group
control
Arm Description
This group of patients will receive a 7-day course of IMPACT ORAL 10 days before the operation.
a retrospective cohort of patients operated on between 2016 and 2019 by nephrectomy cystectomy and laparotomy who did not receive oral impact
Outcomes
Primary Outcome Measures
Rate of major postoperative complications
the number of postoperative complications during this study for each patient
Secondary Outcome Measures
Length of stay in hospital (LOS).
Length of stay in hospital (LOS). durind the participation of each patient
Number of admissions in intensive care setting for severe complications.
Number of admissions in intensive care setting for severe complications after major urological surgery.
Rate of transfusions of red blood cells.
Rate of transfusions of red blood cellsduring hospitalisation and after major urological surgery.
mortality rate
3-month mortality rate
Full Information
NCT ID
NCT05520151
First Posted
August 25, 2022
Last Updated
August 25, 2022
Sponsor
Raincy Montfermeil Hospital Group
1. Study Identification
Unique Protocol Identification Number
NCT05520151
Brief Title
"Influence of Preoperative Immunomodulation by Oral Impact® on Postoperative Complications Following Cystectomies and Nephrectomies
Acronym
IMPACTURO
Official Title
"Influence of Preoperative Immunomodulation by Oral Impact® on Postoperative Complications Following Cystectomies and Nephrectomies
Study Type
Interventional
2. Study Status
Record Verification Date
August 2022
Overall Recruitment Status
Not yet recruiting
Study Start Date
September 2022 (Anticipated)
Primary Completion Date
January 2025 (Anticipated)
Study Completion Date
June 2025 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Raincy Montfermeil Hospital Group
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
any studies have shown the benefit of perioperative Oral Impact immunomodulation in gastrointestinal, ENT, gynaecological and cardiac surgery . Studies in major Urological surgery are rare and are rare and not very contributory. The expected benefit is a reduction in postoperative complications and the average length of stay.
Detailed Description
Major surgery induces a traumatic stress due to the surgical aggression that could lead to major postoperative complications and death when the patient organism is not ready or prepared to support this intense corporeal stress. Malnutrition can be caused by chronic starvation, chronic inflammatory disease and acute injury (stress, acute inflammation). Therefore, nutritional supplements are indicated for patients who do not meet their energy needs through oral food ingestion. Immune-modulating nutrient-enriched products containing arginine, Omega-3 polyunsaturated fatty acids (PUFAs), nucleic acids, vitamins and antioxidants (selenium) like ORAL IMPACT (Nestlé) can modulate immune and inflammatory processes in burn, trauma, major surgery and improve clinical outcomes. These immune-modulating nutrient-enriched products have shown their ability to decrease postoperative complications up to 50% in patients undergoing non-gastrointestinal major surgery and length of hospital and ICU stay (Jie B 2012, Drover 2011). Mortality benefit has been demonstrated in one study focused on Neck and Head surgery. (Buijs N, 2010) Before 2019, in our urology surgery setting, it seemed that the postoperative complications rate was clinically increasing despite reliable surgeons and excellent surgery techniques and procedures. It appeared that the sources of these complications might be the weakness of the patients against major surgical stress. Patients might have been malnourished. The nutrition status had been omitted from our preoperative anesthesia assessment and none perioperative nutritional rehabilitation had been performed.
The effect of immune-modulating nutrient-enriched products had been demonstrated mostly in gastrointestinal surgery but also in non-gastrointestinal surgeries such as neck and head cancer surgery, gynecologic cancer surgery and cardiac surgery. There are not studies conducted in urologic major surgery.
Reducing the number of post-operative complications is a major challenge in surgery because they cause an increase in the length of stay, which translates into higher hospital costs for the community. Surgery is an act that generates major metabolic stress that the human body must contain. This metabolic stress will manifest itself in an increase in catabolism and a decrease in anabolism, resulting in protein-energy malnutrition in the patient if this latter is insufficiently prepared. Preoperative undernutrition is one of the risk factors for major postoperative complications.
Numerous studies have shown the benefit of perioperative Oral Impact immunomodulation in gastrointestinal surgery, ear-nose and throat, gynecological and cardiac surgery.
No studies have been done in major Urological surgery The proposed study will be the first formal evaluation of the benefits and risks of using ORAL IMPACT in preoperative period of urology surgery. The choice of this clinical project for this research question is justified by the proven benefit of this food substitute perioperatively in gastrointestinal, ear-nose and throat, gynecological and cardiac surgery. We hypothesize that Oral Impact will protect against major postoperative complications and prolonged hospital stay for included patients undergoing urological surgery. There are no current guidelines recommending or discouraging the prescription of ORAL IMPACT in urological surgery patients.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Urological Manifestations
Keywords
cystectomy,, nephrectomy,, laparotomies, reduction of postoperative complications
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Single Group Assignment
Model Description
Prospective non-randomized clinical study comparing the group of patients who received a 7-days course of ORAL IMAPCT to a retrospective cohort of patients operated between 2016 and 2019: cystectomy and nephrectomy by laparotomy.
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
214 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
ORAL impact group
Arm Type
Experimental
Arm Description
This group of patients will receive a 7-day course of IMPACT ORAL 10 days before the operation.
Arm Title
control
Arm Type
Other
Arm Description
a retrospective cohort of patients operated on between 2016 and 2019 by nephrectomy cystectomy and laparotomy who did not receive oral impact
Intervention Type
Dietary Supplement
Intervention Name(s)
ORAL IMPACT treatment
Intervention Description
the group of patients will be received a 7-days course of ORAL IMPACT
Intervention Type
Other
Intervention Name(s)
control
Intervention Description
no intervention
Primary Outcome Measure Information:
Title
Rate of major postoperative complications
Description
the number of postoperative complications during this study for each patient
Time Frame
3 months
Secondary Outcome Measure Information:
Title
Length of stay in hospital (LOS).
Description
Length of stay in hospital (LOS). durind the participation of each patient
Time Frame
3 months
Title
Number of admissions in intensive care setting for severe complications.
Description
Number of admissions in intensive care setting for severe complications after major urological surgery.
Time Frame
3 months
Title
Rate of transfusions of red blood cells.
Description
Rate of transfusions of red blood cellsduring hospitalisation and after major urological surgery.
Time Frame
3 months
Title
mortality rate
Description
3-month mortality rate
Time Frame
3 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
18 years of age and older
Scheduled major urological surgery: scheduled: cystectomy, nephrectomy, other laparotomies.
Having expressed their free and informed consent.
Affiliated to a social security scheme
Exclusion Criteria:
Immune deficiency.
HIV infection.
Curative surgery for chronic urinary tract infection.
Urgent surgery.
Inability to take oral impact 7 days before surgery.
Unstable psychiatric state.
Infection with COVID 19 during postoperative stay.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Serge Ndoko, MD
Phone
01.49.36.70.41
Ext
+33
Email
serge.ndoko@ght-gpne.fr
First Name & Middle Initial & Last Name or Official Title & Degree
Sabrina Lassouani, MD
Phone
01.49.36.70.41
Ext
+33
Email
sabrina.lassouani-amara@ght-gpne.fr
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
PubMed Identifier
24009246
Citation
Finnerty CC, Mabvuure NT, Ali A, Kozar RA, Herndon DN. The surgically induced stress response. JPEN J Parenter Enteral Nutr. 2013 Sep;37(5 Suppl):21S-9S. doi: 10.1177/0148607113496117.
Results Reference
result
PubMed Identifier
18419494
Citation
Katona P, Katona-Apte J. The interaction between nutrition and infection. Clin Infect Dis. 2008 May 15;46(10):1582-8. doi: 10.1086/587658.
Results Reference
result
PubMed Identifier
16437757
Citation
Argiles JM. Cancer-associated malnutrition. Eur J Oncol Nurs. 2005;9 Suppl 2:S39-50. doi: 10.1016/j.ejon.2005.09.006.
Results Reference
result
PubMed Identifier
21556200
Citation
Barker LA, Gout BS, Crowe TC. Hospital malnutrition: prevalence, identification and impact on patients and the healthcare system. Int J Environ Res Public Health. 2011 Feb;8(2):514-27. doi: 10.3390/ijerph8020514. Epub 2011 Feb 16.
Results Reference
result
Learn more about this trial
"Influence of Preoperative Immunomodulation by Oral Impact® on Postoperative Complications Following Cystectomies and Nephrectomies
We'll reach out to this number within 24 hrs